The National Cancer Institute in Vilnius and the University Clinic of Kaunas are now ready to start inclusion of patients in Part II of the LPC-004 study. Lithuanian authorities have recently approved the study protocol and the Liproca® Depot injection kits are already on site.
In order to further improve the inclusion rate in Part II of the Phase IIb study, LIDDS has signed agreements with two major hospitals in Lithuania. These very modern and highly respected clinics have a large number of prostate cancer patients that are surveilled on a routine basis. These clinics have the latest diagnostic equipment and have many patients ready for inclusion in the study.
-This expansion is a good way to further increase the inclusion rate and we are happy to be able to involve these respected clinics in the Phase IIb study, says Monica Wallter, CEO LIDDS.
The Phase IIb study will in total include 60 patients with localized prostate cancer being diagnosed as Active Surveillance patients with an elevated risk profile. The purpose of the LPC-004 study is to identify the optimal dose of Liproca® Depot. The study is also being conducted in Canada and Finland and is expected to conclude mid of 2019.
Earlier this year LIDDS signed an exclusive licensing agreement for Liproca®
Depot in China with Jiangxi Puheng.
Liproca® Depot is LIDDS candidate drug for the local treatment of prostate cancer. Based on LIDDS unique NanoZolid® technology, when injected into a tumor, Liproca® Depot releases the active substances over a period of up to six months and the local application avoids the side effects commonly associated with prostate cancer treatments.
Liproca® Depot is one of a number of projects in LIDDS portfolio targeting different cancer treatments using the NanoZolid® technology.
For more information, please contact:
Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, firstname.lastname@example.org
LIDDS is required to disclose the information in this press release under the European Union's Market Abuse Regulation and the Securities Market Act. The information was submitted through the agency of the aforementioned contact person for publication on 21 November 2018 at 08.45 CET.
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in preclinical phase for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North (LIDDS). For more information, please visit liddspharma.com.
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LIDDS AB via Globenewswire